Description of screening programme. The Programme comprises a number of elements which the provider is expected to achieve: • identifying and inviting all eligible people with diabetes for screening at regular intervals (i.e. call/recall) • taking digital images of the eyes of the person with diabetes • grading the digital images of the eyes of the person with diabetes • providing surveillance clinics with slit lamp biomicroscopy assessments • providing surveillance clinics using digital imaging • ensuring people with diabetes with referable eye disease are referred to appropriate hospital eye services/treatment services • undertaking internal quality assurance (QA) • providing clinical oversight and governance for the Programme • In accordance with NHS Screening Programmes’ standards and protocols the provider is expected to fulfil the following • work to nationally agreed NDESP standards, guidance, policies and pathway • implement and support national IT developments • use NHS Screening Programme materials and the protocols for their use • provide timely and accurate performance data • respond to national action/lessons such as change of software, supplier, techniques • work with NHS England and PHE SQAS in reporting on and resolving incidents and serious incidents • report against standard Key Performance Indicators (KPIs) and quality indicators as required • take part in QA processes • implement failsafe procedures according to national guidance and continuously ensure quality • ensure that there is sufficient resource to provide routine (currently annual) digital screening to the defined population • work with commissioners to ensure uptake is maximised and there is equity of access to the service for all people with diabetes. • ensure the workforce is qualified and meeting all NDESP standards • The programme interfaces with and is supported by a number of other services (e.g. primary care, diabetology, hospital eye services and IT support). In order to ensure that the programme delivers a co-ordinated and seamless service in a multi-provider environment, the screening provider must work with any providers that support or deliver other elements of the complete pathway or provide interfacing services and must work to common standards, policies and protocols.
Description of screening programme. The provider is expected to follow, guidance from the national screening programme as detailed in the standards and policies To make sure there is national consistency the provider should: • work to national screening standards • provide data and reports against screening standards, key performance indicators (KPIs), and other measures as requested by the national screening programme • provide data on screening outcomes as required by the national screening programme • make sure appropriate governance structures are in place • take part in quality assurance (QA) processes and implement changes recommended by QA including urgent suspension of services if required • implement and monitor joint checks and audit mechanisms where required to ensure safe and timely processes across the whole screening pathway and drive continuous quality improvement • work with NHS England and NHS Improvement and the screening quality assurance service (SQAS) in reporting, investigating and managing screening safety incidents • respond to national action/lessons for example, change of software, equipment or equipment supplier, new technologies • make sure all health care professionals access appropriate training to maintain continuous professional development and competency • use materials provided by the national screening programme, for example, leaflets, e-learning resources and operational guidance • implement and support national IT developments Screening for Down’s syndrome, Xxxxxxx’ syndrome and Patau’s syndrome is part of the NHS Fetal Anomaly Screening Programme (FASP). In line with NICE guidance (Clinical guideline 62 Antenatal care), all pregnant women should be offered an early ultrasound scan to determine gestational age. The NHS screening programme’s recommended screening tests are gestation dependent, and are as follows: • the combined test can be performed when the crown rump length (CRL) is between 45.0mm to 84.0mm which corresponds to 11+2 to 14+1 weeks of gestation. If the ultrasound measurement shows that the CRL is less than 45.0mm, the woman should be recalled for a further scan to measure the nuchal translucency (NT) • If the CRL is greater than 84.0mm, the second trimester quadruple test should be offered. • the quadruple test which measures four maternal biochemical markers for use in screening for Down’s syndrome only can be performed when the head circumference (HC) is equal to or more than 101.0mm (between 14+2 to 20+0 weeks of pregnancy),
Description of screening programme. Screening for Down’s, Xxxxxxx’ and Patau’s syndromes is part of the NHS Fetal Anomaly Screening Programme (FASP). In line with NICE guidance (Clinical guideline 62 Antenatal care June 2010 xxxx://xxx.xxxx.xxx.xx/guidance/CG62 all pregnant women should be offered an early ultrasound scan to determine gestational age. The NHS screening programme’s recommended screening tests are gestation dependent, and are as follows: • between 10+0 and 14+1 weeks of pregnancy the combined test, which consists of a nuchal translucency scan and a blood test that measures two specific maternal biochemical markers for use in screening for Down’s, Xxxxxxx’ and Patau’s syndromes. • between 14+2 to 20+0 weeks the quadruple test which measures four maternal biochemical markers for use in screening for Down’s syndrome only To complete the ultrasound component of this screening strategy, the scan appointment should allocate time to incorporate pre-scan counselling, the ultrasound examination, post- scan counselling and reporting. The time allocation for appointments to meet these requirements is a minimum of twenty (20) minutes. The results of either test give an individual risk assessment to the woman on the possibility that her baby/ies will have Down’s, Xxxxxxx’ or Patau’s syndromes. If the risk of having a term pregnancy affected with any of these syndromes is 1 in 150 or higher, the pregnancy is regarded as higher risk and the woman will be offered a prenatal diagnostic (PND) test. In January 2016 the UK NSC recommended an evaluative roll out of NIPT to assess what impact it would have on the existing NHS Fetal Anomaly Screening Programme. If the screening test shows that the chance of having a baby with Down’s, Xxxxxxx’ and Patau’s syndromes is higher than 1 in 150, this is called a higher-risk result. Currently, women who have a higher risk result have the option of having an invasive diagnostic test (amniocentesis or CVS). The proposed change is for Non-Invasive Prenatal Testing to be offered to women who are deemed at higher risk following the current primary screen. NIPT is not diagnostic and an invasive diagnostic test is still required to receive a definitive diagnosis. Through 2017-18 the FASP programme will undertake a scoping exercise to plan how NIPT might be integrated into the current screening pathway as an additional option for women with a higher risk result. This will require education and training of all staff contributing to the screening pathway and developm...
Description of screening programme. The UK NSC policy on newborn hearing screening is that all eligible newborn babies in England should be offered screening for bilateral permanent hearing impairment (sensorineural or permanent conductive). Screening should be offered to all babies up to 3 months of age although ideally screening should be performed within days of birth. Those older than 3 months of age, or otherwise not eligible for screening, should be considered for referral to audiology. In delivering a national programme and to ensure national consistency, the local provider is expected to fulfil the following, in conjunction with guidance from the national screening programme where appropriate and as detailed in the programme guidance. • work to nationally agreed programme standards, policies, recommended guidance and pathways • be required to implement and support national IT developments • be required to respond to national actions/lessons such as change of software, equipment supplier, techniques • ensure appropriate governance structures are in place • implement and monitor checks and audit procedures and continuously ensure quality and safety • work with bordering providers to ensure that handover of results or patients is smooth and robust • provide data and reports against programme standards, key performance indicators (KPIs), and quality indicators as required • take part in quality assurance processes and implement changes recommended by QA including urgent suspension of services if required • work with NHS England and NHS Improvement in reporting, investigating and resolving screening incidents and implement agreed actions in accordance to the Managing Safety Incidents in NHS Screening Programmes • provide evidence that all healthcare professionals access and complete appropriate training to maintain continuous professional development and competency • use materials provided by the national programme, e.g. information, leaflets, training resources and guidance • participate in evaluation of the screening programme
Description of screening programme. Screening for Down’s, Xxxxxxx’ and Patau’s syndromes is part of the NHS Fetal Anomaly Screening Programme (FASP). In line with NICE guidance (Clinical guideline 62 Antenatal care June 2010 xxxx://xxxxxxxxxxxx.xxxx.xxx.xx/antenatal-care-cg62 all pregnant women should be offered an early ultrasound scan to determine gestational age. The NHS Screening programme’s recommended screening tests are gestation dependent, and are as follows: • between 10+0 and 14+1 weeks of pregnancy the combined test, which consists of a nuchal translucency scan and a blood test that measures two specific maternal biochemical markers for use in screening for Down’s, Xxxxxxx’ and Patau’s syndromes. • between 14+2 to 20+0 weeks the quadruple test which measures four maternal biochemical markers for use in screening for Down’s syndrome only To complete the ultrasound component of this screening strategy, the scan appointment should allocate time to incorporate pre-scan counselling, the ultrasound examination, post- scan counselling and reporting. The time allocation for appointments to meet these requirements is a minimum of twenty (20) minutes. The results of either test give an individual risk assessment to the woman on the possibility that her baby/ies will have Down’s, Xxxxxxx’ or Patau’s syndromes. If the risk of having a term pregnancy affected with any of these syndromes is 1 in 150 or higher, the pregnancy is regarded as higher risk and the woman will be offered a prenatal diagnostic (PND) test. In delivering a national screening programme and to ensure national consistency the local Provider is expected to fulfill the following, in conjunction with guidance from the National Screening Programme where appropriate and as detailed in the standards and policies available on xxxxx://xxx.xxx.xx/government/publications/fetal-anomaly-screening- programme-standards • work to nationally agreed common standards and policies • be required to implement and support national IT developments • use materials provided by the national screening programme, e.g. leaflets, training media and protocols for their use • be required to respond to national action/lessons such as change of software, equipment supplier, techniques • work with NHS England in reporting, investigating and resolving screening incidents • provide data and reports against programme standards, key performance indicators (KPIs), and quality indicators as required by the national screening programme on behalf of the NHS Screening...
Description of screening programme. The UK National Screening Committee (UK NSC) policy for NIPE is that all eligible babies will be offered the NIPE screen. The screen should be offered within 72 hours of birth and then again at 6-8 weeks of age. The universal offer of screening facilitates early detection of congenital defects of the heart, hips, eyes and testes. Any abnormalities suspected or detected and any clinical concerns identified will lead to a prompt referral for early clinical assessment by the relevant clinical expert. In delivering a national screening programme and to ensure national consistency the local provider is expected to fulfil the following, in conjunction with guidance from the national screening programme where appropriate and as detailed in national policy and standards work to nationally agreed standards and policies be required to implement and support national IT developments be required to respond to national actions such as change of IT software, equipment supplier and techniques ensure appropriate governance structures are in place implement and monitor failsafe procedures and continuously ensure quality and safety work with bordering providers to ensure that handover of results or patients is smooth and robust provide data and reports mapped against programme standards, key performance indicators, and quality indicators as required take part in quality assurance (QA) processes and implement changes recommended by QA including urgent suspension of services if required work with the NHS in reporting , investigating and resolving screening safety incidents and implement agreed actions ensure all health care professionals access and complete appropriate training to maintain continuous professional development and competency use materials provided by the national screening programme, e.g. information leaflets, e-learning and other training resources, and policies to support local service delivery participate in evaluation of the screening programme
